Cargando…
Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up
To identify the risk factors associated with all-cause mortality in patients with noncystic fibrosis bronchiectasis (NCFB). This prospective cohort study included 120 adult patients with NCFB, who were regularly treated at a specialized outpatient clinic of a university hospital between January 2017...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803512/ https://www.ncbi.nlm.nih.gov/pubmed/36596005 http://dx.doi.org/10.1097/MD.0000000000032537 |
_version_ | 1784861903556706304 |
---|---|
author | Mateus, Simone Paulo Ribeiro-Alves, Marcelo Salles, Raquel Esteves Brandão Costa, Walter da Costa, Claudia Henrique Lopes, Agnaldo José Bártholo, Thiago Prudente Mafort, Thiago Thomaz Tura, Bernardo Rangel Rufino, Rogério |
author_facet | Mateus, Simone Paulo Ribeiro-Alves, Marcelo Salles, Raquel Esteves Brandão Costa, Walter da Costa, Claudia Henrique Lopes, Agnaldo José Bártholo, Thiago Prudente Mafort, Thiago Thomaz Tura, Bernardo Rangel Rufino, Rogério |
author_sort | Mateus, Simone Paulo |
collection | PubMed |
description | To identify the risk factors associated with all-cause mortality in patients with noncystic fibrosis bronchiectasis (NCFB). This prospective cohort study included 120 adult patients with NCFB, who were regularly treated at a specialized outpatient clinic of a university hospital between January 2017 and June 2020. All patients were diagnosed using high-resolution computed tomography. Demographic and clinical data, pulmonary function tests, and the Euro-quality-of-life 5-domain 3-level questionnaire were analyzed. The factors associated with death were determined using the Cox proportional hazards model. The all-cause mortality rate at 41 months was 10.8%. Adjusted multivariate analysis showed that the main contributing predictors for mortality were female sex, smoking, diabetes, chronic obstructive pulmonary disease, emergency visits, use of antibiotics due to exacerbation, secretion color change, exacerbation, predicted forced expiratory volume in 1 second, predicted forced vital capacity, lack of respiratory physiotherapy, absence of vaccination against pneumococci, and mobility domain. Multiple factors contribute to unfavorable outcomes in patients with NCFB, and early recognition of these factors may improve care management. |
format | Online Article Text |
id | pubmed-9803512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98035122023-01-03 Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up Mateus, Simone Paulo Ribeiro-Alves, Marcelo Salles, Raquel Esteves Brandão Costa, Walter da Costa, Claudia Henrique Lopes, Agnaldo José Bártholo, Thiago Prudente Mafort, Thiago Thomaz Tura, Bernardo Rangel Rufino, Rogério Medicine (Baltimore) 6700 To identify the risk factors associated with all-cause mortality in patients with noncystic fibrosis bronchiectasis (NCFB). This prospective cohort study included 120 adult patients with NCFB, who were regularly treated at a specialized outpatient clinic of a university hospital between January 2017 and June 2020. All patients were diagnosed using high-resolution computed tomography. Demographic and clinical data, pulmonary function tests, and the Euro-quality-of-life 5-domain 3-level questionnaire were analyzed. The factors associated with death were determined using the Cox proportional hazards model. The all-cause mortality rate at 41 months was 10.8%. Adjusted multivariate analysis showed that the main contributing predictors for mortality were female sex, smoking, diabetes, chronic obstructive pulmonary disease, emergency visits, use of antibiotics due to exacerbation, secretion color change, exacerbation, predicted forced expiratory volume in 1 second, predicted forced vital capacity, lack of respiratory physiotherapy, absence of vaccination against pneumococci, and mobility domain. Multiple factors contribute to unfavorable outcomes in patients with NCFB, and early recognition of these factors may improve care management. Lippincott Williams & Wilkins 2022-12-30 /pmc/articles/PMC9803512/ /pubmed/36596005 http://dx.doi.org/10.1097/MD.0000000000032537 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 6700 Mateus, Simone Paulo Ribeiro-Alves, Marcelo Salles, Raquel Esteves Brandão Costa, Walter da Costa, Claudia Henrique Lopes, Agnaldo José Bártholo, Thiago Prudente Mafort, Thiago Thomaz Tura, Bernardo Rangel Rufino, Rogério Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title | Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title_full | Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title_fullStr | Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title_full_unstemmed | Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title_short | Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
title_sort | mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up |
topic | 6700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803512/ https://www.ncbi.nlm.nih.gov/pubmed/36596005 http://dx.doi.org/10.1097/MD.0000000000032537 |
work_keys_str_mv | AT mateussimonepaulo mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT ribeiroalvesmarcelo mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT sallesraquelestevesbrandao mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT costawalter mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT dacostaclaudiahenrique mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT lopesagnaldojose mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT bartholothiagoprudente mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT mafortthiagothomaz mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT turabernardorangel mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup AT rufinorogerio mortalityandcomorbiditiesinpatientswithbronchiectasisovera3yearfollowup |